The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis

scientific article published on February 2016

The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1002/ACR.22804
P932PMC publication ID4818571
P698PubMed publication ID26806474

P50authorJanet PopeQ48742471
Marco Matucci-CerinicQ19859583
P2093author name stringYannick Allanore
Weng Kee Wong
Maureen D Mayes
Athol U Wells
Christopher P Denton
Dinesh Khanna
James R Seibold
Kristine Phillips
Oliver Distler
Peter A Merkel
Susanna M Proudman
Murray Baron
Janet E Pope
Shervin Assassi
Robert W Simms
Virginia Steen
Daniel E Furst
Philip J Clements
Edward H Giannini
Elena Schiopu
Sindhu R Johnson
Veronica J Berrocal
Jeffrey Siegel
P2860cites workSkin thickness score as a predictor and correlate of outcome in systemic sclerosis: high-dose versus low-dose penicillamine trialQ46623011
American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritisQ47643186
Frequency and impact of symptoms experienced by patients with systemic sclerosis: results from a Canadian National SurveyQ48327217
Clinical trial design in scleroderma: where are we and where do we go next?Q48562434
A note on a general definition of the coefficient of determinationQ56505617
Strictly Proper Scoring Rules, Prediction, and EstimationQ56553210
Measurement of patient outcome in arthritisQ56879288
Development of classification and response criteria for rheumatic diseasesQ57244852
Analysis of improvement in individual rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs, based on the findings in patients treated with placebo. The Cooperative Systematic Studies of Rheumatic Diseases GroupQ67285449
Responsiveness to change: an aspect of validity, not a separate dimensionQ67481757
A disease severity scale for systemic sclerosis: development and testingQ73101147
Severe organ involvement in systemic sclerosis with diffuse sclerodermaQ73202420
A randomized, controlled trial of methotrexate versus placebo in early diffuse sclerodermaQ74024124
BILAG-2004 index captures systemic lupus erythematosus disease activity better than SLEDAI-2000Q80370140
What is the relationship between disease activity, severity and damage in a large Canadian systemic sclerosis cohort? Results from the Canadian Scleroderma Research Group (CSRG)Q84583792
Trends in mortality in patients with systemic sclerosis over 40 years: a systematic review and meta-analysis of cohort studiesQ26864958
Mortality in systemic sclerosis: an international meta-analysis of individual patient dataQ30980001
Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity scoreQ33563148
Validity of single variables and composite indices for measuring disease activity in rheumatoid arthritisQ33567430
ATS StatementQ34136219
Assessment of kidney involvement.Q34218311
Definitions and diagnosis of pulmonary hypertension.Q34393150
Cyclophosphamide versus placebo in scleroderma lung disease.Q34540647
Concepts of functioning and health important to people with systemic sclerosis: a qualitative study in four European countries.Q34905661
Methods of formal consensus in classification/diagnostic criteria and guideline developmentQ35091202
Current status of outcome measure development for clinical trials in systemic sclerosis. Report from OMERACT 6.Q35176779
Correlates and responsiveness to change of measures of skin and musculoskeletal disease in early diffuse systemic sclerosisQ35878701
Patterns and predictors of change in outcome measures in clinical trials in scleroderma: an individual patient meta-analysis of 629 subjects with diffuse cutaneous systemic sclerosisQ35977294
Old medications and new targeted therapies in systemic sclerosisQ36154430
Scleroderma: from cell and molecular mechanisms to disease modelsQ36259889
Systemic sclerosis - continuing progress in developing clinical measures of response.Q36810200
Outcome measures in systemic sclerosis: an update on instruments and current researchQ36821503
A severity scoring tool to assess the neurological features of neuronopathic Gaucher diseaseQ36944847
Recombinant human relaxin in the treatment of systemic sclerosis with diffuse cutaneous involvement: a randomized, double-blind, placebo-controlled trial.Q37013037
Course of the modified Rodnan skin thickness score in systemic sclerosis clinical trials: analysis of three large multicenter, double-blind, randomized controlled trialsQ37301159
Quality indicator set for systemic sclerosis.Q37460639
Development of a provisional core set of response measures for clinical trials of systemic sclerosisQ37460792
Validity, reliability, and feasibility of durometer measurements of scleroderma skin disease in a multicenter treatment trialQ37460808
Measures of response in clinical trials of systemic sclerosis: the Combined Response Index for Systemic Sclerosis (CRISS) and Outcome Measures in Pulmonary Arterial Hypertension related to Systemic Sclerosis (EPOSS).Q37612672
The Systemic Lupus Erythematosus Responder Index (SRI); a new SLE disease activity assessmentQ37940672
Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon.Q39632069
Disease and symptom burden in systemic sclerosis: a patient perspective.Q40197495
European Scleroderma Study Group to define disease activity criteria for systemic sclerosis. IV. Assessment of skin thickening by modified Rodnan skin scoreQ43050321
Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE.Q44441787
P433issue2
P304page(s)167-178
P577publication date2016-02-01
P1433published inArthritis Care and ResearchQ15754720
P1476titleThe American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis
P478volume68